Business Wire

The Japanese Culinary Academy Launches japanese-cuisine.com, a Website with Killer Content and an E-Learning Program to Promote Japanese Cuisine Abroad

11.9.2019 00:00:00 EEST | Business Wire | Press release

Share

The Japanese Culinary Academy, located in Kyoto Prefecture, Yoshihiro Murata, Director, and online at https://culinary-academy.jp/english, has partnered with Blue Magic, Inc., headquartered in Tokyo, Yukiko Akimoto, CEO, and online at https://bluemagic.co.jp/, to develop jointly an e-learning program that teaches the culture and technique of authentic Japanese cuisine. Services began worldwide on July 12, 2019.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005448/en/

There is a boom right now for Japanese cuisine around the world, with a rapid increase in Japanese restaurants everywhere you go. At present there are more than 120,000 Japanese restaurants globally.

The Japanese Culinary Academy, as part of their efforts for an accurate understanding of Japanese cuisine throughout the world, dispatches instructors for seminars held globally on Japanese cuisine. It also accepts students from abroad who study Japanese cuisine in Japan, and has published in English and other languages a serial journal on Japanese cuisine, among other activities.

By virtue that the Japanese Culinary Academy is a ministry-certified organization, as defined by the Guidelines for Certification of Cooking Skills for Japanese Cuisine in Foreign Countries, set by Japan’s Ministry of Agriculture, Forestry, and Fisheries on April 1, 2016, it has developed the japanese-cuisine.com e-learning program to reasonably teach the culture and techniques of Japanese cuisine, at any location in the world and at any time, covering the level of knowledge and skill required for Bronze certification within those Guidelines.

The online site is at https://japanese-cuisine.com.

The Japanese Culinary Academy is positioning this program as killer content for the promotion of Japanese cuisine worldwide. As the sales arm of this effort, Blue Magic, Inc., is seeking sales partners to proliferate this promotion.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Inquiries:
Terumi Oyagi
office@culinary-academy.jp
The Japanese Culinary Academy

Inquiries regarding partners for supporting publications in other languages:
Ayumi Kuji
contact@japanese-cuisine.com
Blue Magic, Inc.

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors9.9.2026 16:45:00 EEST | Press release

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been awarded the Lasker-DeBakey Clinical Medical Research Award, one of the world's most prestigious scientific honors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909923883/en/ From left: Dr. Kitazawa, Dr. Hattori, and Dr. Igawa Hemophilia A is caused by a deficiency of coagulation Factor VIII, one of the proteins required for normal blood clotting. When activated, Factor VIII serves as a bridge that facilitates the activation of Factor X by activated Factor IX on the surface of activated platelets. The award recognizes the unconventional concept of replacing this function of Factor VIII with a

AMCS Appoints Richard Humphrey as Chief Product and Technology Officer9.9.2026 16:00:00 EEST | Press release

AMCS, a leading technology provider for the waste and recycling industry, today announced the appointment of Richard Humphrey as Chief Product and Technology Officer. Based in Boston, Humphrey will lead the company’s global product organisation. Humphrey brings more than 25 years of experience developing software for construction and other complex industrial environments. He joins AMCS as the company deepens its focus on waste and recycling and expands the role of AI across its platform. Most recently, Humphrey served as Chief Product and Technology Officer at Contruent, where he led product strategy for a construction cost-management platform used on major capital programmes. He previously held vice president roles at Bentley Systems and B2W Software. Earlier in his career, he spent more than a decade at Autodesk, where he led its Civil Design and Construction software business as Senior Director. “Richard understands what it takes to build software for industries where the work is ex

BBH Launches a New Technology Business, Braid, Solving for Intelligent Data Transformation9.9.2026 15:45:00 EEST | Press release

Brown Brothers Harriman (BBH) today announced the launch of a new technology affiliate, Braid LLC, focused on solving enterprise data transformation for financial services. Braid offers an AI-native data transformation platform that gives firms a scale solution to transform, connect, and manage their data with confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909294398/en/ Braid empowers teams to build, automate, and oversee reliable production-grade data transformations in a fraction of the time typically required today. Instead of requiring engineers to build data automations, Braid allows business users to describe their needs in natural language that AI agents use to build intelligent data transformations that are transparent and fully auditable. Braid’s enterprise-grade engine then processes and delivers those data transformations in a controlled and deterministic environment. Built by financial services exp

LTM Collaborates with IBM and Red Hat on Lightwell to Advance AI-Driven Open-Source Software Remediation9.9.2026 15:30:00 EEST | Press release

LTM, the Business Creativity partner to the world's largest enterprises, today announced that it has collaborated with IBM and Red Hat on Lightwell to help enterprises safeguard the open-source software supply chain through AI-driven vulnerability remediation. As AI accelerates the discovery of software vulnerabilities, organizations must move beyond detection-focused approaches and adopt enterprise-scale remediation strategies that enable rapid risk mitigation without disrupting business-critical applications. Lightwell’s approach of delivering validated fixes for production environments aligns with LTM's aim of helping customers build secure, resilient, and operationally efficient software supply chains. By combining AI-powered remediation capabilities with enterprise-grade validation and deployment support, Lightwell aims to help organizations address security challenges across increasingly complex open-source ecosystems. Building on its long-standing status as an IBM Platinum Partn

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life9.9.2026 15:24:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1. "People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily life,” said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-861-3001) Phase 3 study. “The newly published Phase 3 data reinforce the potential of oveporexton to transform how we approach narcolepsy type 1 in clinical practice, shifting from managing individual symptoms to treating the disease itself.” NT1 is a chronic, rare neurological disease driven by orexin deficiency. As a result, people experience a range of daytime and nighttime symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye